Please login to the form below

Not currently logged in
Email:
Password:

Diabetes drug gets good review

The Committee for Medicinal Products for Human use (CHMP) has recommended that a new medicine to treat Type II diabetes be approved for use in Europe.

The Committee for Medicinal Products for Human use (CHMP) has recommended that a new medicine to treat Type II diabetes be approved for use in Europe.

Sitagliptin/metformin has been developed to provide a significant reduction in glucose levels in patients with diabetes. The drug was licensed for use in the UK in 2007 and is manufactured under the brand name Janumet by Merck Sharp & Dhome. The company could potentially be in a position to supply its branded medicine to 27 countries in the European market, including Norway and Iceland, should regulatory authorities adopt CHMP's recommendation.

Kamlesh Khunti, professor of primary care diabetes and vascular medicine at the University of Leicester, said: "Many patients remain poorly controlled on their existing oral combination therapy. In order to improve quality of life for our patients, we need simple and effective treatments that address glucose control and common tolerability issues such as hypoglycaemia and weight gain."

A 30-week placebo-controlled clinical study showed that sitagliptin/metformin had a high level of efficacy when reducing blood sugar levels. A decision regarding marketing authorisation by the European Medicines Agency (EMEA) is expected in mid June 2008.

25th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics